NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Medesis Pharma SA (PA: ALMDP)
ALMDP Technical Analysis
5
As on 21st Nov 2024 ALMDP STOCK Price closed @ 0.43 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.15 & Strong Sell for SHORT-TERM with Stoploss of 1.39 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ALMDPSTOCK Price
Open | 0.47 | Change | Price | % |
High | 0.52 | 1 Day | 0.02 | 4.88 |
Low | 0.41 | 1 Week | 0.03 | 7.50 |
Close | 0.43 | 1 Month | 0.10 | 30.30 |
Volume | 151589 | 1 Year | -1.40 | -76.50 |
52 Week High 1.88 | 52 Week Low 0.33 |
PA France Most Active Stocks
ALNEV | 0.00 | % |
FTI | 5.91 | -1.66% |
VIEDS | 0.72 | 4.35% |
ALVER | 0.00 | % |
ATO | 0.16 | -15.79% |
ALMAS | 0.01 | 0.00% |
CGG | 0.69 | -2.82% |
ALDRV | 0.00 | % |
ELIOR | 2.75 | -11.86% |
ALHYG | 0.01 | 0.00% |
PA France Top Gainers Stocks
PA France Top Losers Stocks
ALMDP Daily Charts |
ALMDP Intraday Charts |
Whats New @ Bazaartrend |
ALMDP Free Analysis |
|
ALMDP Important Levels Intraday
RESISTANCE | 0.64 |
RESISTANCE | 0.57 |
RESISTANCE | 0.53 |
RESISTANCE | 0.49 |
SUPPORT | 0.37 |
SUPPORT | 0.33 |
SUPPORT | 0.29 |
SUPPORT | 0.22 |
ALMDP Forecast November 2024
4th UP Forecast | 0.89 |
3rd UP Forecast | 0.74 |
2nd UP Forecast | 0.65 |
1st UP Forecast | 0.56 |
1st DOWN Forecast | 0.3 |
2nd DOWN Forecast | 0.21 |
3rd DOWN Forecast | 0.12 |
4th DOWN Forecast | -0.03 |
ALMDP Weekly Forecast
4th UP Forecast | 1.05 |
3rd UP Forecast | 0.85 |
2nd UP Forecast | 0.73 |
1st UP Forecast | 0.60 |
1st DOWN Forecast | 0.26 |
2nd DOWN Forecast | 0.13 |
3rd DOWN Forecast | 0.01 |
4th DOWN Forecast | -0.19 |
ALMDP Forecast2024
4th UP Forecast | 4.42 |
3rd UP Forecast | 3.14 |
2nd UP Forecast | 2.35 |
1st UP Forecast | 1.56 |
1st DOWN Forecast | -0.7 |
2nd DOWN Forecast | -1.49 |
3rd DOWN Forecast | -2.28 |
4th DOWN Forecast | -3.56 |
Medesis Pharma SA ( PA France Symbol : ALMDP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ALMDP Other Details
Segment | EQ | |
Market Capital | 24417232.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
ALMDP Address
ALMDP Latest News
ALMDP Business Profile
Medesis Pharma SA, a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 ? NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France. Address: L'Orée des Mas, Montpellier, France, 34670
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service